Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.65 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.47 |
| ▸ | F7 | P08709 | 4/20 | 0.47 |
| ▸ | F3 | P13726 | 4/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.42 |
| ▸ | HAT1 | O14929 | 2/20 | 0.40 |
| ▸ | EP300 | Q09472 | 2/20 | 0.40 |
| ▸ | GPR6 | P46095 | 6/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7147985 | 0.92 | F10 (0.56) | F10PRSS1PRSS2F7F3 | |
| SCHEMBL6875241 | 0.92 | F10 (0.56) | F10PRSS1PRSS2F7F3 | |
| SCHEMBL6875968 | 0.92 | F10 (0.56) | F10PRSS1PRSS2F7F3 | |
| SCHEMBL6872647 | 0.91 | F10 (0.54) | F10PRSS1PRSS2F7F3 | |
| SCHEMBL7147090 | 0.90 | F10 (0.53) | F10PRSS1PRSS2F7F3 | |
| SCHEMBL6874415 | 0.90 | F10 (0.52) | F10PRSS1PRSS2F7F3 | |
| SCHEMBL6874426 | 0.89 | F10 (0.52) | F10 | |
| SCHEMBL6871337 | 0.88 | F10 (0.51) | F10PRSS1PRSS2F7F3 | |
| SCHEMBL7150817 | 0.88 | F10 (0.51) | F10PRSS1PRSS2F7F3 | |
| SCHEMBL6871497 | 0.86 | F10 (0.49) | F10PRSS1PRSS2F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474391-A1 | WATER SOLUBLE PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-6642386-B2 | Having alkoxy, halo and piperidin-4-yl substituents; water soluble; coagulation factors Xa and IXa, thrombin induced factor VIIa and tissue factor inhibitors | HOFFMANN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030166683-A1 | N-(4-CARBAMIMIDOYL-PHENYL)-GLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
| WO-2003066588-A1 | WATER SOLUBLE PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166683-A1 | N-(4-CARBAMIMIDOYL-PHENYL)-GLYCINE DERIVATIVES | F2, F12, F5 | F10 7/4885PRSS1 62/4885PRSS2 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.